P-Shot for erectile dysfunction

The P-Shot, formally trademarked as the Priapus Shot, is a specific, proprietary commercial protocol for injecting platelet-rich plasma (PRP) into the penis, marketed to men seeking improvement in erectile function, sensitivity, or overall sexual performance. PRP itself is not unique to this product — it's prepared by drawing a small amount of a man's own blood, spinning it in a centrifuge to concentrate the platelets (which contain numerous growth factors involved in tissue repair and, in laboratory studies, blood vessel formation), and then injecting this concentrated plasma into specific areas of the penis. The P-Shot is one particular, branded version of this broader technique, with its own specific, trademarked preparation, activation, and injection process, developed and marketed by a specific physician and company.

Understanding this distinction — between "PRP for ED" as a general medical concept being studied in research, and "the P-Shot" as a specific, trademarked commercial product — is genuinely important, and it's one of the more unusual aspects of writing honestly about this particular treatment. Nearly all of the published, peer-reviewed research discussed below studies generic intracavernosal (or subcutaneous) PRP injection using various preparation methods described in each specific study, not the exact, proprietary P-Shot protocol itself. When PRP research has shown disappointing results, the P-Shot's own trademark holder has specifically argued, in response, that the branded protocol differs meaningfully in its preparation, activation, and injection technique from what was studied — which may or may not be true, but which also means, taken to its logical conclusion, that the specific commercial product being sold under this trademark has essentially no independent, peer-reviewed verification of its own. This is worth understanding clearly before anything else on this page, because it shapes how much weight the research below can actually be given when applied specifically to a P-Shot treatment, as opposed to PRP injection in general.

Turning to the broader body of PRP-for-ED research itself, the picture is genuinely, unusually mixed — more so than for most other treatments covered on this site, including even low-intensity shockwave therapy, which has its own significant evidence-quality caveats. On one side, several recent meta-analyses, pooling data from multiple randomized and single-arm trials, report a statistically significant benefit. A November 2024 meta-analysis combining 12 controlled trials (991 patients) and 11 single-arm trials (377 patients) found the PRP group showed better outcomes on the International Index of Erectile Function (IIEF) score and a measure called the Minimal Clinically Important Difference, concluding that PRP "appears effective" while explicitly calling for further high-quality, larger trials with longer follow-up. A separate systematic review and meta-analysis of randomized controlled trials, published in mid-2024, similarly concluded that PRP "shows more effectiveness in treating ED compared to placebo." A third analysis, using meta-regression across six studies, found PRP intracavernous injection associated with a statistically significant increase in IIEF erectile function domain scores at both one and three months compared with control groups.

On the other side — and this is genuinely important, not a minor footnote — one of the more methodologically rigorous individual studies conducted specifically to test this question directly found the opposite result. A prospective, double-blind, randomized, placebo-controlled trial, presented at the American Urological Association's 2023 Annual Meeting and reported as winning a "best abstract" award at that meeting, concluded plainly that PRP "was not more efficacious than placebo." The study's lead researcher was direct in his framing of this finding, noting that PRP injections for ED are "really popular, but, objectively speaking, so far, we don't have any evidence showing that it actually works" using a properly blinded, placebo-controlled design of this kind. This is a genuinely important, sobering counterpoint to the more positive pooled meta-analyses discussed above, and it's worth understanding why these findings might diverge: the meta-analyses combine studies using considerably varied PRP preparation methods, dosing, activation techniques, and follow-up periods — described in a 2025 narrative review as showing "significant variability" that "hindered" the ability to draw firm, unified conclusions — meaning the pooled positive signal may partly reflect this methodological heterogeneity and the inclusion of weaker, less rigorously controlled studies, rather than a single, dependable, reproducible clinical effect.

Reflecting this genuine, unresolved uncertainty, the European Association of Urology's current guideline position — discussed specifically in the context of Peyronie's disease, but reflecting the same underlying evidence base and general caution that extends to PRP's use in erectile dysfunction — explicitly classifies PRP as an experimental therapy, recommending that its use be restricted to formal clinical trials rather than offered as a standard, evidence-supported clinical treatment outside of that research context. This is a meaningfully more cautious position than exists for, say, low-intensity shockwave therapy, where major guideline bodies at least describe it as an emerging or investigational option worth discussing, rather than something that should currently be restricted to trials only.

It's worth being honest about the proposed mechanism too, separate from the clinical trial evidence. The theoretical rationale for PRP in erectile dysfunction draws on its use in other areas of regenerative medicine, where concentrated platelets are thought to release growth factors that can, in laboratory and some animal studies, promote new blood vessel formation (angiogenesis) and tissue repair — a mechanism with some genuine biological plausibility, not dissimilar in principle to the mechanotransduction theory behind shockwave therapy. But biological plausibility in laboratory settings is a different thing from confirmed, reproducible clinical benefit in men, and this is precisely the gap that the conflicting human trial evidence described above hasn't yet closed.

None of this means PRP or the P-Shot specifically is dangerous, or that no man has ever experienced genuine improvement after having it — some men do report satisfaction with the treatment, and because it uses a man's own blood, the direct physical risk profile is genuinely low, discussed further below. What it does mean, and what this page aims to convey honestly rather than soften, is that this is currently one of the least settled treatments discussed on this site, sitting somewhere between the encouraging-but-uncertain evidence picture for low-intensity shockwave therapy and the more directly discouraged, professional-body-skeptical territory of standalone girth enhancement procedures — closer, if anything, to the latter, given the existence of a directly contradicting, well-designed placebo-controlled trial and an explicit guideline recommendation restricting use to clinical trials only.